MicroRNA-134 as a potential target to reduce seizures and sudden death in a mouse model of Dravet syndrome

Ant-134 treatment had no effect on seizure incidence or mortality in Dravet syndrome mice.

• Dravet syndrome is characterized by severe seizures that are often resistant to treatment.
• MicroRNA-134 is involved in regulating gene expression related to brain function.
• Inhibiting miR-134 with Ant-134 has previously shown promise in reducing seizures in other models.
• The study assessed the effectiveness of Ant-134 in preventing hyperthermia-induced seizures and sudden unexpected death in epilepsy (SUDEP) in Dravet syndrome mice.
• No significant changes were observed in seizure incidence or mortality rates in the Ant-134 treated group compared to untreated mice.
• The findings indicate that targeting miR-134 may not provide therapeutic benefits for Dravet syndrome.

Simplified